ZNF281 and rhabdomyosarcoma: In agreement with the results obtained with TMA, the analysis of publicly available datasets of soft tissue sarcomas confirmed a significantly higher expression of ZNF281 in leiomyosarcoma, rhabdomyosarcoma, dedifferentiated liposarcoma, and myxoid/round cell liposarcoma (Hawkins et al., 2013) patients compared with normal counterparts (Figs 4A and S3A,B).